Last updated: February 17, 2026
What is the current market status of drug NDC 23155-0787?
NDC 23155-0787 corresponds to NexoBrid (insoluble, comprising bromelain enzymes). It is an enzymatic debridement agent indicated for removing eschar in burn wounds. Approved by the FDA in 2014, NexoBrid holds a specific niche within the burn management space, serving as an alternative to surgical debridement.
Market penetration remains limited due to factors such as:
- Strict approval conditions
- Limited reimbursement pathways
- Competition from traditional surgical methods and off-label enzymatic products
Global sales are concentrated mainly in North America and Europe, with growth potential in emerging markets driven by increasing burn incidents and acceptance of enzymatic therapies.
How does NexoBrid compare to existing debridement options?
| Attribute |
Surgical Debridement |
Enzymatic (NexoBrid) |
| Speed |
Immediate, but operator-dependent |
Slower, requires application period (~4-8 hours) |
| Specificity |
Less selective |
Highly selective for necrotic tissue |
| Pain |
Can induce significant discomfort |
Reduced pain, less invasive |
| Healing Time |
Varies, dependent on procedure and wound care |
Potentially faster due to precise removal |
| Reimbursement |
Widely covered, high variability |
Limited, varies by payer |
Growth in enzymatic debridement approval and adoption hinges on cost-effectiveness evidence and insurance coverage.
What are the price dynamics for NexoBrid?
Pricing varies by region and payer systems. In the U.S., the average wholesale price (AWP) per treatment course ranges between $3,000 and $5,000. Given the typical clinical course involves applying NexoBrid for 1-2 days, total treatment costs may reach approximately $4,500.
In comparison, traditional surgical debridement entails higher hospitalization costs (average $30,000 per burn case), factoring in operative procedures and extended stays. NexoBrid's acquisition cost is often offset by shorter hospital stays and reduced operative interventions.
International pricing reflects regional healthcare systems, with European reimbursement rates approximately 20-30% lower than the U.S. levels. Emerging markets demonstrate sensitivity to cost, limiting market penetration without subsidy programs.
What are the projections for NexoBrid’s market growth and pricing?
Market growth estimates
Forecasts from market research firms gauge the global enzymatic debridement market at a compound annual growth rate (CAGR) of approximately 8% from 2022 to 2027[1].
Key drivers include:
- Rising burn injury prevalence
- Increased approval and adoption of enzymatic debridement
- Technological improvements decreasing application time
Price trajectory
Price projections suggest a stabilization or slight decrease over the next five years, primarily due to:
- Competitive pressure from alternative therapies
- Entry of biosimilar or generic enzyme formulations
- Healthcare cost containment efforts
By 2027, average treatment course prices are anticipated to decline marginally to between $3,000 and $4,500 across most regions.
Market expansion potential
Emerging economies could see accelerated growth through:
- Adoption of enzymatic debridement as a cost-effective alternative
- Increasing burn incidence rates
- Supportive healthcare policies
However, reimbursement limitations and lack of local approval may impede rapid market penetration initially.
What challenges could influence future market and pricing?
- Limited insurance coverage outcomes
- Competition from surgical methods and off-label enzyme use
- Regulatory hurdles in expanding indications
- Cost sensitivity in developing markets
Manufacturers may pursue value-based pricing strategies, emphasizing clinical benefits and reduced total care costs.
Key Takeaways
- NexoBrid (NDC 23155-0787) is a specialized enzymatic debridement product primarily used in burn care.
- Market size remains constrained by reimbursement and clinical adoption barriers, with growth driven by burn incidence and new approvals.
- Current pricing ranges from $3,000 to $5,000 per treatment in the U.S.; international prices are lower.
- Market projections show an approximate 8% CAGR up to 2027, with prices gradually decreasing due to competitive and cost containment factors.
- Future expansion depends on regional regulatory approvals, reimbursement improvements, and competitive innovations.
FAQs
1. What is the main advantage of NexoBrid over traditional surgical debridement?
It provides highly selective removal of necrotic tissue, reduces pain, and can potentially shorten healing times and hospital stays.
2. Are there biosimilar or generic versions of NexoBrid?
As of 2023, no biosimilars or generics are approved; the drug remains under patent protection and exclusivity.
3. How significant is reimbursement to NexoBrid’s market adoption?
Reimbursement remains a critical factor; limited coverage in some regions constrains adoption, especially in cost-sensitive markets.
4. What are the primary barriers to global expansion?
Regulatory approvals, reimbursement limitations, and clinical familiarity with enzymatic debridement influence market penetration.
5. Will the price decrease impact profitability for manufacturers?
Moderate price reductions are expected, but volume growth and expansion into emerging markets may offset margin pressures.
Sources
[1] MarketWatch, "Global Enzymatic Debridement Market Outlook," 2022.
